|
LSUHSC-S recognizes the need for a robust research portfolio and seeks to promote an environment conducive to creating opportunities for faculty to participate in research across disciplines that is relevant and conducted in a safe, ethical manner. In order to support the discovery portion of its mission to “Teach. Heal. Discover.” The institution has provided the resources and guidance covered in this section.
12.1 Oversight
Leadership. LSUHSC’s research leadership team is responsible for driving scientific discovery, supporting faculty and researchers, and ensuring compliance with ethical standards and regulatory requirements. Key leadership roles include:
- Vice Chancellor for Research Administration: Oversees research operations, including grant and contract management, regulatory compliance, financial oversight, reporting, and policy development to support and manage the research process.
- Senior Associate Dean for Clinical Research: Oversees clinical research initiatives, fostering innovation and collaboration to enhance research outcomes and clinical practice.
- Associate Dean for Basic and Translational Research: Leads the institution’s efforts in advancing scientific discovery through basic and translational research initiatives by fostering collaborations across departments, guiding faculty in identifying funding opportunities, ensuring compliance with institutional and regulatory standards, and supporting faculty development.
Office for Sponsored Programs. The Office for Sponsored Programs (OSP) supports research faculty and staff in securing extramural funding for basic and translational research. OSP is the authorized institutional office for submitting research funding proposals, ensuring all proposals are reviewed and administratively approved before submission to external agencies. The office assists with identifying funding sources, reviewing award terms, and ensuring compliance with federal, state, and institutional requirements. Additionally, OSP manages grant activities, including progress reporting, re-budgeting, grant close-outs, and grant transfers, and facilitates sponsored research agreements, material transfer agreements, confidentiality agreements, and federal subcontracts. OSP also tracks and reports research funding for sponsored projects. It is located on the second floor of the Biomedical Research Institute, and more information is available on the OSP website (link).
Clinical Trials Office. The Clinical Trials Office (CTO) provides administrative, research, and educational support to LSUHSC-S researchers conducting clinical trials. Its goals include facilitating clinical trials research by offering regulatory and administrative assistance, educating researchers on clinical research policies and best practices, coordinating community outreach to raise awareness and increase trial participation, and fostering partnerships with industry to recruit new clinical trials. The CTO is located on the 2nd floor of the Administration Building, Room 203B. More information on its services and resources is available on the CTO website (link).
Office of Innovation, Commercialization and Technology Transfer. The Office of Innovation, Commercialization and Technology Transfer (OICTT) supports LSUHSC-S faculty and staff in developing intellectual property. Its mission is to protect, nurture, and accelerate academic discoveries by managing and safeguarding the institution’s intellectual property, facilitating commercialization through various contracts, protecting investigators’ interests, ensuring compliance with government regulations, and helping build long-term industry relationships. More information about OICTT can be found at OICTT website (link).
Human Research Protection Program. The Human Research Protection Program (HRPP) at LSUHSC-S ensures the ethical and safe conduct of human research by overseeing studies involving human subjects. The HRPP aims to protect the rights, safety, and well-being of human research subjects, provide timely and thorough review and monitoring of research projects, and promote excellence in human subject research. The Clinical Trials Office (CTO) and the Institutional Review Board (IRB) staff administer the HRPP, ensuring compliance with federal, state, and institutional regulations, while providing education, resources, and monitoring for researchers. The HRPP is accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP).
Animal Care and Use Committee. The Animal Care and Use Committee (ACUC) oversees the care and use of animals in research, teaching, and testing. The committee conducts semi-annual program reviews and facility inspections, evaluates compliance with federal regulations, investigates concerns, and reviews protocols related to animal use. It makes recommendations to the Institutional Official and has the authority to approve, modify, or suspend activities involving animals. The committee includes faculty, veterinarians, non-affiliated representatives, and institutional staff. For the complete ACUC charter, please refer to Article IV of the LSUHSC-S Faculty Bylaws.
Institutional Biosafety Committee (IBC). The Institutional Biosafety Committee (IBC) oversees biological and chemical safety in research, ensuring compliance with NIH Guidelines for recombinant DNA research. The IBC develops institutional policies, reviews research protocols, advises investigators, and conducts safety training. The committee assesses laboratory biosafety levels, investigates violations, updates safety manuals, and communicates with other institutional oversight committees. Membership includes faculty experts in biosafety, genetics, and microorganisms, as well as external representatives for public health and environmental concerns. For the complete IBC charter, please refer to Article IV of the LSUHSC-S Faculty Bylaws.
Institutional Review Board. The Institutional Review Board (IRB) oversees the ethical review of all research involving human subjects, ensuring their rights, safety, and welfare. Operating under the Institutional Official, the IRB consists of at least five diverse members with expertise in scientific and non-scientific areas, including individuals knowledgeable about vulnerable populations. The IRB establishes procedures for initial and ongoing review, determines necessary reporting protocols, and ensures compliance with federal regulations. The IRB also investigates unanticipated risks, noncompliance, and suspensions, reporting findings to institutional and federal authorities as required. For the complete IRB charter, please refer to Article IV of the LSUHSC-S Faculty Bylaws.
Radiation Safety Committee. The Radiation Safety Committee oversees the safe use of ionizing and non-ionizing radiation and radioactive materials at the institution, excluding those associated with the Ochsner/LSUHSC-S Health Care Services Divisions. It ensures proper training for personnel, approves procurement of radioactive materials, and reviews projects, facilities, and radiation monitoring equipment. The committee ensures compliance with OSHA regulations for ionizing radiation and LSU system safety procedures for non-ionizing radiation. For the complete Radiation Safety Committee charter, please refer to Article IV of the LSUHSC-S Faculty Bylaws.
Radioactive Drug Research Committee. The Radioactive Drug Research Committee is responsible for reviewing research projects involving the experimental use of radioactive substances in humans, specifically for studies focused on metabolism, human physiology, pathophysiology, or biochemistry, but not for clinical trials. The committee operates under the authority of the Chancellor. For the complete Radioactive Drug Research Committee charter, please refer to Article IV of the LSUHSC-S Faculty Bylaws.
12.2 Research Compliance, Integrity, and Management
Conflict of Interest. LSUHSC-S Administrative Directive 2.8.15: Conflicts of Interest outlines the procedures and guidelines for managing Conflicts of Interest (COI) and Financial Conflicts of Interest (FCOI) at LSUHSC-S, ensuring that research, education, and service are conducted with the highest ethical standards. The directive aligns with federal and state regulations to protect the integrity of research by identifying and managing any potential or actual COIs that may compromise the objectivity of research design, conduct, or reporting. It emphasizes transparency, requiring all relevant individuals to disclose financial interests annually through the SHIELDS system, and updates must be made within 30 days of acquiring new significant financial interests. The policy includes a detailed process for evaluating and managing COIs, with a Conflicts of Interest Review Committee (COIRC) overseeing the implementation of management plans to mitigate any identified conflicts. The directive also outlines institutional obligations, including the disclosure of financial interests related to patents, equity, and large gifts, and mandates training on COI for all research personnel. Non-compliance with the policy is subject to review and corrective actions. For full details, please refer to Administrative Directive 2.8.15.
LSU Permanent Memorandum 11 requires all full-time LSU employees to disclose and obtain approval for any outside employment to ensure it does not conflict with their university duties, with further details outlined in Section 6.5 of the Faculty Handbook.
LSU Permanent Memorandum 67 outlines the conditions under which faculty members or entities in which they have an interest may enter into contracts with the university, as permitted by Louisiana law. These agreements are allowed under specific circumstances, such as those involving patents, copyrights, licensing rights, or royalties from research conducted during the faculty member’s tenure at LSU. The policy ensures that such contracts promote economic development while maintaining transparency and preventing conflicts of interest. Faculty members must disclose ownership interests, recuse themselves from decision-making, and allow an independent LSU representative to handle contract negotiations. Further details are provided in Section 6.6 of the Faculty Handbook.
[LSUHSC-S. (12/2/2024). Administrative Directive 2.8.15: Conflicts of Interest.]
[LSU. (5/12/1993). Permanent Memorandum 11: Outside Employment of University Employees.]
[LSU. (10/6/1997). Permanent Memorandum 67: Contracts between the University and its Faculty Members]
Placement of Sponsored Agreements. LSU Permanent Memorandum 27: Placement of Sponsored Agreements mandates that all sponsored project proposals submitted in the University’s name must be awarded to the University, ensuring institutional benefits such as recognition, publication opportunities, and reimbursement for indirect costs. Employees transferring research must do so within the University, and awards cannot be diverted to outside organizations without explicit approval from the President when required by the sponsor. If a Principal Investigator (PI) leaves the University, the institution retains authority over grant transfers, typically seeking to retain multi-PI awards. However, if the sponsoring agency deems the departing PI critical to the project’s success, the University will facilitate the transfer to the PI’s new institution.
[LSU. (4/21/1998). Permanent Memorandum 27: Placement of Sponsored Agreements.]
Extramural Research Proposals. LSUHSC-S Administrative Directive 4.6: Extramural Research Proposals outlines the procedures for obtaining institutional approval for externally funded research projects. The Office for Sponsored Programs (OSP) is responsible for reviewing, approving, and submitting all proposals on behalf of LSUHSC-S to ensure compliance with institutional and funding agency requirements. Proposals must be entered into the Cayuse Research Suite for internal review at least 30 business days before the sponsor’s deadline, with final submissions required 10 business days in advance. Late proposals are reviewed on a case-by-case basis but may not be submitted if adequate review time is not provided.
[LSUHSC-S. (6/9/2023). Administrative Directive 4.6: Extramural Research Proposals.]
Closing out Grants and Contracts. LSUHSC-S Administrative Directive 1.1.8: Closing Out Grants and Contracts outlines the procedure for closing out grants, contracts, and clinical trials, following state, federal, and institutional regulations. Financial records must be closed within 90 days of the grant or contract’s termination, with residual funds distributed according to specific policies. If indirect costs (IDC) have been collected, 75% of residual funds go to research infrastructure support and 25% to the Principal Investigator’s Research Development Account. For contracts with no IDC, 50% of the residual funds are transferred to LSUHSC-S’ general fund. The closeout procedure includes ensuring all expenditures, commitments, and cost-sharing obligations are satisfied, and final fiscal reports are submitted to the grantor within 90 days. Fixed-price and cost-reimbursement grants have distinct procedures, including handling unexpended funds and ongoing obligations. Continuation grants require transferring expenses to continuation accounts and clearing outstanding commitments. Additionally, principal investigators must ensure that all financial obligations are met, and no charges are incurred after the termination date unless authorized.
[LSUHSC-S. (7/21/2023). Administrative Directive 1.1.8: Closing Out Grants and Contracts.]
Elimination of Grant and Contract Account Overdrafts. LSUHSC-S Administrative Directive 1.1.9: Elimination of Grant and Contract Account Overdrafts outlines the procedures for resolving overdrafts in grant and contract accounts. Departments will receive monthly notifications when their accounts have overdrafts and are required to take corrective action by the specified deadline. If the department fails to act, Grants and Contracts Accounting (GCA) will transfer the expenditures to the departmental indirect cost recovery (IDC) or operating account. GCA will continue to monitor expenditures on sponsored programs and alert departments to any significant discrepancies. Once overdrafts are cleared and no further financial activity is authorized, the accounts may be closed or deactivated.
[LSUHSC-S. (7/21/2023). Administrative Directive 1.1.9: Elimination of Grant and Contract Account Overdrafts.]
Repositories of Human Tissue and Databanks for Research Purposes. Chancellor Memorandum 33: Repositories of Human Tissue and Databanks for Research Purposes establishes policy for the collection, storage, and use of human tissue and data for research. The policy ensures compliance with federal, state, and institutional regulations, including HIPAA and IRB requirements, to protect human research subjects and sensitive information. It applies to all LSUHSC-S employees and affiliated researchers, requiring IRB approval before establishing repositories or conducting research using stored specimens or data. Repositories must implement strict privacy, security, and informed consent procedures that outline future research use, data access, and confidentiality protections. Researchers accessing repository materials must adhere to IRB-approved agreements, ensuring compliance with ethical and legal standards. While some projects using de-identified data may qualify for exemption, the IRB determines eligibility on a case-by-case basis.
[LSUHSC-S. (8/23/2010). Chancellor Memorandum 33: Repositories of Human Tissue and Databanks for Research Purposes.]
Ordering Laboratory Animals and Related Equipment. LSUHSC-S Administrative Directive 3.7: Ordering Laboratory Animals and Special Animal Housing, Caging, or Equipment provides the procedures for requisitioning and purchasing laboratory animals and related equipment at LSUHSC-S. Departments are required to submit requisitions for laboratory animals using a designated form, including necessary details such as the principal investigator’s name, protocol and account numbers, and any special requirements. All requests for animal purchases must be routed to the Office of Animal Resources for approval before proceeding to the Purchasing Department. Requests for special housing, caging, or equipment must also be approved by the Director of Animal Resources and submitted via the PeopleSoft requisition system. All requisitions are processed in accordance with procurement guidelines, and principal investigators are not permitted to order animals directly outside of this established procedure.
[LSUHSC-S. (12/14/2022. Administrative Directive 3.7: Ordering Laboratory Animals and Special Animal Housing, Caging, or Equipment.]
Payments to Participants in Research Trials. LSUHSC-S Administrative Directive 4.1: Payments to Participants in Research Trials outlines the policy and procedures for reimbursing participants in research trials, including time and travel expenses. LSUHSC-S employees can participate in research studies and receive reimbursement, provided it does not conflict with their job duties or IRB policies. The Clinical Trials Office (CTO), in collaboration with the principal investigator and study coordinators, manages reimbursements according to the IRB-approved study protocols and contract terms. Payments must comply with IRS guidelines. Referral fees for recruitment purposes are prohibited, and reimbursement costs are covered by the study sponsor or funding source. Reimbursements are processed and disbursed after study visits and lost or stolen reimbursement methods may incur fees.
[LSUHSC-S. (1/3/2023). Administrative Directive 4.1: Payments to Participants in Research Trials.]
Disclosure of Funding Sources in Applications for Federal Research. LSUHSC-S Administrative Directive 4.3: Disclosure of Funding Sources in Applications for Federal Research and Development Awards establishes the procedures for disclosing funding sources in federal research award applications. In compliance with federal law, individuals listed on these applications must disclose their current and pending research support, including details on the amount, type, and source, and certify the accuracy and currency of this information.
[LSUHSC-S. (12/14/2022). Administrative Directive 4.3: Disclosure of Funding Sources in Applications for Federal Research and Development Awards.]
Time and Effort Reporting and Certification. LSUHSC-S Administrative Directive 4.4: Time and Effort Reporting and Certification for Federal Grants outlines the procedures for reporting and certifying effort for federal grants. In accordance with federal regulations, LSUHSC-S employees receiving federal sponsored funding must verify the effort devoted to these projects, ensuring that salaries charged to grants are consistent with the actual work performed. The institution uses an after-the-fact effort reporting system, where employees estimate the time spent on various activities and certify their effort distribution. The Office of Sponsored Programs (OSP) monitors and reviews effort certifications, ensuring compliance with institutional policies and federal requirements. Certification is required every six months, and discrepancies or changes in effort must be addressed through updated reports. Effort changes must be approved by OSP, and adjustments are made when necessary to align with funding and effort commitments.
[LSUHSC-S. (4/12/2024). Administrative Directive 4.4: Time and Effort Reporting and Certification for Federal Grants.]
Cost Sharing Reporting for Research Grants. LSUHSC-S Administrative Directive 4.5: Cost Sharing Reporting for Research Grants establishes guidelines for managing cost sharing on sponsored projects. Cost sharing refers to the specific portion of project costs funded by LSUHSC-S and not by the sponsor, which includes quantifiable costs like percent of effort or dollar amounts listed in the proposal budget, narrative, or award document. It ensures compliance with federal regulations, specifically 2 CFR 200, and outlines procedures for tracking, documenting, and reporting cost sharing contributions. The directive specifies that cost sharing must be included in the proposal if required by the sponsor and must be approved by the department and the Office for Sponsored Programs (OSP) before submission. It also provides criteria for expenditures to qualify as cost sharing, emphasizing proper documentation and alignment with award terms and conditions. Non-compliance or failure to meet cost sharing commitments could result in reductions to allowable costs and potential refunds to the sponsoring agency.
[LSUHSC-S. (2/3/2023). Administrative Directive 4.5: Cost Sharing Reporting for Research Grants.]
Revision of Grants Transfer Events. LSUHSC-S Administrative Directive 4.7: Revision of Grants Transfer Events outlines procedures for managing movable property acquired through grants at LSUHSC-S, ensuring compliance with state and federal property control regulations. It applies to all equipment purchased with grant funds and requires departments to work with Asset Management to update inventory records for new, purchased, and donated assets. The policy sets guidelines for acquiring assets, tagging them with identification tags within 60 days of receipt, and documenting installations. Additionally, it covers the handling of donated assets, including those from the LSUHSC-S Foundation or incoming faculty, ensuring proper tagging and record-keeping for all assets.
[LSUHSC-S. (4/22/2024). Administrative Directive 4.7: Revision of Grants Transfer Events.]
Indirect Cost. LSU Permanent Memorandum 10: Indirect Cost Allowances on Grants and Contracts ensures recovery of expenses incurred by the university for externally funded projects. Grants classified as outright gifts with no specific obligations are exempt from indirect cost charges. However, grants that impose meaningful responsibilities, benefit the grantor, or require specialized resources are subject to these charges. The applicable indirect cost rate aligns with the federally negotiated rate agreement, with exceptions allowed under specific conditions, such as student benefits, economic development, or funding restrictions from non-profit organizations. The Chancellor of each campus has the authority to modify the policy within stricter limits, and deviations require approval from the Office of the President.
LSUHSC-S Administrative Directive 1.1.10: Distribution of Indirect Costs outlines the distribution procedures for indirect costs (IDC) at LSUHSC-S. The policy aims to incentivize full overhead recovery to support research, attract top faculty, compensate research support units, and ensure the development of innovative projects. IDC is distributed quarterly, with 70% allocated to the institution for research infrastructure, 20% to the department, and 10% to the Research Core Facility. Additional funds may be allocated to principal investigators (PIs) to support their research activities. Specific guidelines are provided for various types of research, including federal and private basic science, non-pharmaceutical clinical trials, and pharmaceutical clinical trials, with detailed allocation percentages and conditions for each.
LSUHSC-S Chancellor Memorandum 24 establishes the indirect cost (IDC) policy for industry-sponsored and private entity-sponsored research agreements, emphasizing the role of external funding in supporting research operations, staffing, and facility maintenance. The federally approved Facilities & Administrative (F&A) cost rate applies to federal grants and contracts, while industry-sponsored pharmaceutical research carries a 35% IDC rate, supporting compliance, clinical trials, and other institutional research functions. IDC from private entity-funded basic research follows the federal distribution model, and no IDC is assessed for internally sponsored research.
[LSU. (9/26/1991). Permanent Memorandum 10: Indirect Cost Allowances on Grants and Contracts.]
[LSUHSC-S. (9/21/2023). Administrative Directive 1.1.10: Distribution of Indirect Costs.]
[LSUHSC-S. (5/1/2019). Chancellor Memorandum 24: Indirect Cost for Industry Sponsored and Private Entity Sponsored Research Agreements]
Lab Space Allocation. Administrative Directive 6.29: Lab Space Allocation outlines the allocation of research lab space at LSUHSC-S, prioritizing faculty with active, externally funded research that includes full indirect cost recovery. Lab space assignments are reviewed annually based on funding metrics to ensure alignment with institutional goals. The Chancellor has final authority over space decisions, with the Associate Dean for Basic and Translational Research serving as an advisor. The Laboratory Space Allocation and Review Committee oversees the policy’s implementation and evaluates space requests. Faculty must meet specific funding levels to retain space, and newly recruited faculty with external funding may receive lab space for up to five years. Exceptions to the policy require approval from the Chancellor.
For full details on procedures and requirements, please refer to Administrative Directive 6.29 at this link.
[LSUHSC-S. (1/1/2025). Administrative Directive 6.29: Lab Space Allocation.]
Reporting Misconduct in Research. LSUHSC-S seeks excellence in discovery and dissemination of knowledge while maintaining high standards and ethical practices in research conduct. Dishonesty, fraud, and misconduct in research erode the reputations and credibility of investigators, institutions, and the scientific community at large and are not tolerated at LSUHSC-S.
All allegations of misconduct in research are evaluated promptly with due regard for the reputation and rights of all individuals involved. Complainants acting in good faith who make allegations of research misconduct will be protected from retaliation in accordance with federal and University requirements.
LSUHSC-S Policy and Procedures for Dealing with Allegations of Research Fraud follow the U.S. Department of Health and Human Services Public Health Service (PHS) Policies on Research Misconduct. Research misconduct is defined as fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results.
- Fabrication is making up data or results and recording or reporting them.
- Falsification is manipulating research materials, equipment, or processes, or changing or omitting data or results such that the research is not accurately represented in the research record.
- Plagiarism is the appropriation of another person’s ideas, processes, results, or words without giving appropriate credit.
Research misconduct does not include honest errors and ambiguities of interpretation.
When the institution receives an allegation of research misconduct, an initial inquiry is conducted to determine if the evidence of misconduct is sufficient to proceed with a full investigation. If there is sufficient evidence of misconduct, a full investigation is initiated to evaluate evidence. The Investigation Committee assesses whether misconduct has occurred and determines responsibility. In conducting the inquiry and investigation, the institution makes every effort to ensure that: (1) persons involved in the evaluation of the allegations and evidence have appropriate expertise; (2) no person involved in the procedures is biased against the accused person(s) or has a conflict of interest; and (3) affected individuals receive confidential treatment to the maximum extent possible.
If misconduct in research is determined to have occurred, the institution will provide research sponsors relevant information of the findings and penalties. In addition, journal editors will be notified, if necessary. In misconduct cases involving PHS-funded research, LSUHSC-S is obligated to keep the U.S. Office of Research Integrity appropriately informed and to protect federal funds.
For more information regarding research misconduct, visit the U.S. Office of Research Integrity website at their website (link).
[LSUHSC-S]
12.3 Intellectual Property and Technology Transfer
The policies governing intellectual property and technology transfer at LSU are designed to support and encourage innovation while ensuring compliance with legal and institutional guidelines. Full details on these policies are outlined in the LSU Board of Supervisors Rules and Regulations, specifically in Article VII. Additional information can also be found on the institution’s Office of Innovation, Commercialization, and Technology Transfer website. This office is dedicated to protecting, nurturing, and accelerating academic discoveries by managing and safeguarding the institution’s intellectual property, facilitating commercialization through various agreements, protecting investigators’ interests, ensuring compliance with government regulations, and fostering long-term industry relationships.
General Policy. The University encourages and expects its personnel to engage in creative, scholarly activities as part of their duties. All University Personnel are required to disclose to the appropriate campus officer, at an early date, any discoveries, inventions, and works potentially subject to legal protection under patent, copyright, or other law. The inventor, the inventor’s department, and the inventor’s campus gain prestige, and in some cases financial benefits, from commercializing an invention or discovery. Such commercialization is consistent with, and complementary to, the University’s academic mission; through such activities, the University provides new benefits to the public and enhances economic development.
[LSU Board of Supervisors. (2/23/2024). Regulations, Article VII, Section 1: General Policy. LSU Board of Supervisors Rules and Regulations.]
Ownership and Management of LSU Intellectual Property. LSU owns all intellectual property created by its personnel, who are required to assign their rights to the University. LSU has full discretion to manage, license, patent, or dispose of intellectual property as it sees fit, including making decisions on financial benefits. Any agreement related to LSU intellectual property must be approved by the University, and unauthorized transfers are void. If the University decides not to manage certain intellectual property, it may assign it to the creator upon written request. LSU may also waive its rights to intellectual property in exceptional cases, such as consulting agreements with outside employers, provided these agreements comply with University policies. Additionally, the University typically does not accept restrictions on publication but may agree to temporary delays to accommodate sponsors or licensees, with conditions ensuring minimal restrictions and consent from affected personnel.
[LSU Board of Supervisors. (2/23/2024). Regulations, Article VII, Section 3: Ownership and Management of LSU Intellectual Property. LSU Board of Supervisors Rules and Regulations.]
Allocation of Distributable Royalties. Forty percent of royalties are allocated to the inventors or authors, to be paid within thirty days of receipt by the University, with continued payments even if they leave the University. Inventors may request that their royalties be retained for research support or directed to other LSU personnel. The University retains 5% for the Office of the President and LSU LIFT Fund, and 50% is allocated to the appropriate campus. Royalties may be held for distribution if payments are less than $250. Corporate equity received by the University is managed by the President, who may sell or transfer it based on consultation with financial professionals, avoiding conflicts of interest. If multiple inventors or entities are involved, royalty distribution is handled by unanimous consent or the President’s decision. Special circumstances, such as litigation proceeds or research grants, are addressed with specific distribution guidelines.
[LSU Board of Supervisors. (2/23/2024). Regulations, Article VII, Section 4: Allocation of Distributable Royalties. LSU Board of Supervisors Rules and Regulations.]
General Requirements for Licenses and Other Agreements. The University will not license or encumber IP that is incomplete at the time of the agreement, except for specific rights granted to research sponsors. It requires that licensees obtain prior approval before transferring or assigning IP rights and outlines conditions for sublicensing, including the need for sublicensees to adhere to the original terms and provide copies of agreements. Licensees must also obtain appropriate liability insurance, with the University named as an additional insured. Licensees and sublicensees are expected to indemnify the University against claims related to the IP. The University typically does not permit brokerage of IP but may allow exceptions under certain conditions. When the University assigns or waives IP rights to authors or inventors, it does so without warranties, and these individuals are responsible for obtaining necessary third-party licenses or clearances. Any substantial deviation from these policies must be approved by the President based on a recommendation from the Chancellor.
[LSU Board of Supervisors. (2/23/2024). Regulations, Article VII, Section 5: General Requirements for Licenses and Other Agreements. LSU Board of Supervisors Rules and Regulations.]
Uniform Process for Managing Technology Transfer. All commercialization activities, including purchases, sales, transfers, assignments, and licenses, must follow this standardized procedure across all campuses and institutions. License agreements require approval from the President, who may delegate this authority. The University has developed standard templates for commercialization transactions, and campuses must use these templates, justifying any deviations. Reporting on commercialization activities must be submitted to the President and Board, including details on potential conflicts of interest, due diligence conducted on the intellectual property and licensees, and any deviations from standard agreements.
[LSU Board of Supervisors. (2/23/2024). Regulations, Article VII, Section 6: Uniform Process for Managing Technology Transfer at the University. LSU Board of Supervisors Rules and Regulations.]
LSU Works, LSU Software, LSU Databases, LSU Digital Media, and Course Materials. The University generally releases copyright ownership of literary and artistic works to their authors, except when the University publishes or produces derivative works, or when contractual obligations require retention. Course Materials remain the author’s property only for personal instructional use, and LSU reserves rights for internal distribution. Prior to external submission, LSU Digital Media must be reviewed to determine ownership classification. When the University publishes or licenses LSU Works or Databases, a portion of net sales is allocated as Distributable Royalties. However, faculty do not receive tuition-based compensation for University use of their materials in instruction, though royalties may be distributed if third-party licensing occurs.
[LSU Board of Supervisors. (2/23/2024). Regulations, Article VII, Section 7: LSU Works, LSU Software, LSU Databases, LSU Digital Media, and Course Materials. LSU Board of Supervisors Rules and Regulations.]
Confidential Materials. University and campus officials have the authority to protect confidential materials exempt from the Louisiana Public Records Law. The President, Chancellor, technology transfer officers, and designated individuals may certify in writing that requested materials fall under a specific statutory exemption, ensuring compliance with legal protections.
[LSU Board of Supervisors. (2/23/2024). Regulations, Article VII, Section 8: Confidential Materials. LSU Board of Supervisors Rules and Regulations.]
Agreement to Assume Liability of Patent Costs. Chancellor Memorandum 26: Agreement to Assume Liability of Patent Costs provides a mechanism for individual faculty members to fund patent prosecution when institutional support is unavailable due to a lack of interest or funding. Faculty members who choose to participate must agree in writing to assume financial responsibility for the patent process, with the understanding that the patent will still be assigned to LSU, regardless of institutional backing. The agreement requires approval from the faculty member’s department head and includes a financial disclosure submitted to the Office of Sponsored Programs and Technology Transfer. Even if a faculty member funds the patent, ownership remains with LSU, though they may continue research supporting the application. LSUHSC-S will attempt to market the invention if deemed viable, but licensing and cost recovery are not guaranteed. Any recovered funds will be returned to the original funding source.
[LSUHSC-S. (n.d.). Chancellor Memorandum 26: Agreement to Assume Liability of Patent Costs]
12.4 Research Resources
Animal Resources. Animal Resources, located on the 9th floor of the Medical School B Building, provides essential support for animal-based research, ensuring the humane care and ethical use of animals in scientific studies. The facility offers comprehensive animal husbandry care, veterinary services, and specialized equipment, all managed by a skilled team dedicated to maintaining optimal health and welfare for the animals. It supports a variety of research needs, ensuring compliance with regulatory standards and ethical guidelines. For inquiries, contact Facility Operations (animal husbandry care) at 318-675-5651, Veterinary Services at 318-675-5204, or Administration at 318-675-5200.
Research Core Facility. The Research Core Facility, located on the 6th floor of the Biomedical Research Institute, offers core resources and services to support scientific research across multiple disciplines. It is equipped with cutting-edge technology and instrumentation, providing access to specialized equipment and technical expertise. Key offerings include an Automated Cellular Imaging System, Confocal Microscopy, DNA Array (Chip) Analysis, Flow Cytometry, Fluorescence Microscopy, Laser Capture Microdissection, Mass Spectrometry-Proteomics, DNA Sequencing, and Real-Time PCR. In addition, the Small Animal Imaging Facility, located on the 9th floor of the Medical School B Building, features advanced imaging tools such as MicroPET, MicroCT, MicroPET/SPECT/CT, and fluorescent imaging systems.
For more information, please visit the Research Core Facility’s website (link).
|